Antibody/siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem-Like Behavior in Triple-Negative Breast Cancer Cells

Overview

Journal J Biomed Mater Res A

Specialty Biomedical Engineering

Date 2025 Jan 6

PMID 39760151

Authors

Elise C Hoover

Emily S Day

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is infamous for its aggressive phenotype and poorer prognosis when compared to other breast cancer subtypes. One factor contributing to this poor prognosis is that TNBC lacks expression of the receptors that available hormonal or molecular-oriented therapies attack. New treatments that exploit biological targets specific to TNBC are desperately needed to improve patient outcomes. One promising target for therapeutic manipulation is the Wnt signaling pathway, which has been associated with many invasive breast cancers, including TNBC. This pathway is activated in TNBC cells when extracellular Wnt ligands bind to overexpressed Frizzled7 (FZD7) transmembrane receptors, leading to downstream activation of intracellular β-catenin proteins. To target and inhibit Wnt signaling in TNBC cells, polymer nanoparticles (NPs) modified with anti-FZD7 antibodies and β-catenin small interfering RNAs (siRNAs) were developed, and their impact on the oncogenic behavior of treated TNBC cells was investigated. When compared to control NPs, the Wnt-targeted NPs induced greater levels of Wnt oncogene suppression. This led to greater inhibition of oncogenic and stem-like properties, including cell proliferation, drug resistance, and spheroid formation capacity. This work demonstrates a promising approach for targeting the Wnt pathway in TNBC to counter the cellular phenotypes that drive disease progression.

References

Kanasty R, Whitehead K, Vegas A, Anderson D . Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012; 20(3):513-24. PMC: 3293611. DOI: 10.1038/mt.2011.294. View

Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan Y . FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 30(43):4437-46. DOI: 10.1038/onc.2011.145. View

Qian L, Mahaffey J, Alcorn H, Anderson K . Tissue-specific roles of Axin2 in the inhibition and activation of Wnt signaling in the mouse embryo. Proc Natl Acad Sci U S A. 2011; 108(21):8692-7. PMC: 3102376. DOI: 10.1073/pnas.1100328108. View

Chen X, Duan N, Zhang C, Zhang W . Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016; 7(3):314-23. PMC: 4747886. DOI: 10.7150/jca.13332. View

Abravanel D, Belka G, Pan T, Pant D, Collins M, Sterner C . Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015; 125(6):2484-96. PMC: 4497740. DOI: 10.1172/JCI74883. View

Paramanantham A, Jung E, Kim H, Jeong B, Jung J, Kim G . Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling. Int J Mol Sci. 2021; 22(22). PMC: 8623267. DOI: 10.3390/ijms222212438. View

Vadnais C, Shooshtarizadeh P, Rajadurai C, Lesurf R, Hulea L, Davoudi S . Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. Biol Open. 2014; 3(10):937-46. PMC: 4197442. DOI: 10.1242/bio.20148193. View

Woythe L, Tito N, Albertazzi L . A quantitative view on multivalent nanomedicine targeting. Adv Drug Deliv Rev. 2020; 169:1-21. DOI: 10.1016/j.addr.2020.11.010. View

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

10.

Huang Z, Yu P, Tang J . Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model. Onco Targets Ther. 2020; 13:5395-5405. PMC: 7295545. DOI: 10.2147/OTT.S249756. View

11.

Macleod R . MDR-1, Bcl-xL, H. pylori, and Wnt/β-catenin signalling in the adult stomach: how much is too much?. Lab Invest. 2012; 92(12):1670-3. DOI: 10.1038/labinvest.2012.151. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Hansen K, Ji H, Wu G, Datar R, Cote R, Majumdar A . Cantilever-based optical deflection assay for discrimination of DNA single-nucleotide mismatches. Anal Chem. 2001; 73(7):1567-71. DOI: 10.1021/ac0012748. View

14.

Scully M, Wilhelm R, Wilkins D, Day E . Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer. ACS Biomater Sci Eng. 2024; 10(3):1355-1363. PMC: 10939768. DOI: 10.1021/acsbiomaterials.4c00160. View

15.

Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z . Frizzled7 Promotes Epithelial-to-mesenchymal Transition and Stemness Via Activating Canonical Wnt/β-catenin Pathway in Gastric Cancer. Int J Biol Sci. 2018; 14(3):280-293. PMC: 5859474. DOI: 10.7150/ijbs.23756. View

16.

Hoover E, Ruggiero O, Swingler R, Day E . FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer. ACS Omega. 2024; 9(12):14323-14335. PMC: 10976388. DOI: 10.1021/acsomega.3c10275. View

17.

Yang S, May S . Release of cationic polymer-DNA complexes from the endosome: A theoretical investigation of the proton sponge hypothesis. J Chem Phys. 2008; 129(18):185105. DOI: 10.1063/1.3009263. View

18.

Park J, Evangelopoulos M, Vasher M, Kudruk S, Ramani N, Mayer V . Enhancing Endosomal Escape and Gene Regulation Activity for Spherical Nucleic Acids. Small. 2023; 20(11):e2306902. PMC: 10947971. DOI: 10.1002/smll.202306902. View

19.

Smith S, Cui Y, Bustamante C . Overstretching B-DNA: the elastic response of individual double-stranded and single-stranded DNA molecules. Science. 1996; 271(5250):795-9. DOI: 10.1126/science.271.5250.795. View

20.

Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M . Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022; 21(1):144. PMC: 9281132. DOI: 10.1186/s12943-022-01616-7. View